
    
      This study is a multi-center, multinational, randomized, double-blind, placebo-controlled
      Phase II clinical trial. Study enrollment will comprise approximately 225 patients meeting
      study inclusion requirements. The study will be conducted at up to 80 multinational
      investigational sites. Eligible patients will be randomized (2:1) into one of two 6 month
      treatment groups. One group (approximately 150 patients) will receive R788 150 mg PO bid; the
      other treatment group (approximately 75 patients) will receive placebo.
    
  